keyword
Keywords Benralizumab: for Eosinophilic...

Benralizumab: for Eosinophilic asthma

https://read.qxmd.com/read/38183647/differences-in-asthma-related-outcomes-by-anti-il-5-biologics-omalizumab-and-dupilumab-based-on-blood-eosinophil-counts
#21
JOURNAL ARTICLE
Yuya Kimura, Maho Suzukawa, Norihiko Inoue, Shinobu Imai, Hiromasa Horiguchi, Manabu Akazawa, Hirotoshi Matsui
BACKGROUND: Selecting optimal biologics based on type 2 biomarkers has been of interest in severe asthma treatment. However, few direct biomarker stratification-based comparisons have been made. OBJECTIVE: To compare the effectiveness of anti-IL-5 (mepolizumab, benralizumab), omalizumab, and dupilumab in reducing the number of hospitalizations from asthma and exacerbations across all and eosinophil-stratified subgroups. METHODS: A retrospective cohort study using the National Hospital Organization database (2016-2020) was performed...
January 6, 2024: Asian Pacific Journal of Allergy and Immunology
https://read.qxmd.com/read/38155862/identification-of-biologic-responsive-phenotypes-in-elderly-people-with-eosinophilic-asthma
#22
JOURNAL ARTICLE
Olga Prokunina, Faoud T Ishmael
BACKGROUND: Asthma in the elderly is not as well studied as in younger age groups. Age-related immunosenescence may result in diminished TH 2 inflammation, which raises a question about whether asthma in elderly patients responds well to anti-TH 2 asthma biologics. OBJECTIVE: We sought to determine whether asthma in elderly people has different TH 2 biomarkers and clinical features compared to nonelderly people, and if disease in the 2 age groups responds differently to anti-TH 2 biologics...
February 2024: J Allergy Clin Immunol Glob
https://read.qxmd.com/read/38151952/eosinophil-to-lymphocyte-ratio-may-predict-ocs-reduction-and-change-in-quality-of-life-aqlq-resulting-from-asthma-biological-treatment
#23
JOURNAL ARTICLE
Olga Branicka, Radosław Gawlik, Joanna Glück
OBJECTIVES: Simple clinical parameters that could be helpful in choice of monoclonal antibodies and prediction of their effectiveness are being sought. The aim was to assess if neutrophil-to-lymphocyte, eosinophil-to-lymphocyte and platelet-to-lymphocyte ratios may predict outcomes of biologic therapy for severe asthma. METHODS: retrospective, single-centre study including severe asthma patients treated with three different biologics. The blood ratios were assessed at initiation of treatment (point 0) and after six months (point 1)...
December 27, 2023: Immunopharmacology and Immunotoxicology
https://read.qxmd.com/read/38093952/a-comparison-of-treatment-response-to-biologics-in-asthma-copd-overlap-and-pure-asthma-findings-from-the-prism-study
#24
JOURNAL ARTICLE
Ji-Su Shim, Hyunkyoung Kim, Jae-Woo Kwon, So-Young Park, Sujeong Kim, Byung-Keun Kim, Young-Hee Nam, Min-Suk Yang, Mi-Yeong Kim, Sae-Hoon Kim, Byung-Jae Lee, Taehoon Lee, Sang-Ha Kim, So Young Park, Young-Joo Cho, Chan Sun Park, Jae-Woo Jung, Han-Ki Park, Joo-Hee Kim, Jeong-Hee Choi, Ji-Yong Moon, Ian Adcock, Kian Fan Chung, Min-Hye Kim, Tae-Bum Kim
BACKGROUND: Despite the increasing use of biologics in severe asthma, there is limited research on their use in asthma-chronic obstructive pulmonary disease overlap (ACO). We compared real-world treatment responses to biologics in ACO and asthma. METHODS: We conducted a multicenter, retrospective, cohort study using data from the Precision Medicine Intervention in Severe Asthma (PRISM). ACO was defined as post-bronchodilator forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) <0...
December 2023: World Allergy Organization Journal
https://read.qxmd.com/read/38071986/reduction-of-daily-maintenance-inhaled-corticosteroids-in-patients-with-severe-eosinophilic-asthma-treated-with-benralizumab-shamal-a-randomised-multicentre-open-label-phase-4-study
#25
RANDOMIZED CONTROLLED TRIAL
David J Jackson, Liam G Heaney, Marc Humbert, Brian D Kent, Anat Shavit, Lina Hiljemark, Lynda Olinger, David Cohen, Andrew Menzies-Gow, Stephanie Korn
BACKGROUND: Stepwise intensification of inhaled corticosteroids (ICS) is routine for severe eosinophilic asthma, despite some poor responses to high-dose ICS. Dose reductions are recommended in patients responding to biologics, but little supporting safety evidence exists. METHODS: SHAMAL was a phase 4, randomised, open-label, active-controlled study done at 22 study sites in four countries. Eligible participants were adults (aged ≥18 years) with severe eosinophilic asthma and a five-item Asthma Control Questionnaire score below 1·5 and who received at least three consecutive doses of benralizumab before screening...
January 20, 2024: Lancet
https://read.qxmd.com/read/38054593/exacerbations-treatment-patterns-utilization-and-costs-before-and-after-initiating-of-benralizumab-for-the-treatment-of-severe-eosinophilic-asthma
#26
JOURNAL ARTICLE
Joseph L Smith, Yen Chung, John Barron, Theodore Barlows, Bal Nepal, Donna Carstens
ObjectivesThe purpose of this study was to examine the number of exacerbations, counts of eosinophils, and asthma-related symptoms one year before and after initiating benralizumab for the treatment of severe eosinophilic asthma.MethodsPatients with prior exacerbations and newly initiating benralizumab were identified in the claims-based Healthcare Integrated Research Database. Claims were used to assess benralizumab treatment patterns, exacerbations, healthcare resource utilization, and other asthma medication used...
December 6, 2023: Journal of Asthma
https://read.qxmd.com/read/38053108/factors-influencing-poor-response-to-type-2-targeted-therapies-in-severe-asthma-a-retrospective-cohort-study
#27
JOURNAL ARTICLE
Mona Al-Ahmad, Asmaa Ali, Ahmed Maher
BACKGROUND: A significant breakthrough has been made in treating severe asthma, with the recognition of various asthma phenotypes and an updated management guideline. Type 2 targeted therapies, such as benralizumab and omalizumab; have been identified as an effective treatment for severe asthma, improving patient response, lung function tests and asthma symptom control. This study aimed to evaluate factors contributing to poor response to therapy. METHODS: A retrospective single-center cohort study of 162 patients with severe asthma who started biologic therapy; their data were retrieved from medical records for further analysis...
December 5, 2023: BMC Pulmonary Medicine
https://read.qxmd.com/read/38020567/benralizumab-in-severe-eosinophilic-asthma-in-real-life-confirmed-effectiveness-and-contrasted-effect-on-sputum-eosinophilia-versus-exhaled-nitric-oxide-fraction-promise
#28
JOURNAL ARTICLE
Florence Schleich, Catherine Moermans, Laurence Seidel, Céline Kempeneers, Gilles Louis, Florence Rogister, Sophie Tombu, Laurence Pottier, Anne-Lise Poirrier, Stéphanie Ziant, Monique Henket, Carole Sanchez, Virginie Paulus, Françoise Guissard, Anne-Françoise Donneau, Renaud Louis
BACKGROUND: Randomised controlled trials have shown that benralizumab, an anti-interleukin-5 receptor monoclonal antibody, reduces exacerbations and oral corticosteroid dose and improves asthma control and lung function in severe eosinophilic asthma. The aim of this study was to confirm results of randomised controlled trials in real life in a population of 73 patients with severe eosinophilic asthma treated with benralizumab for at least 12 months. METHODS: Patients underwent careful monitoring of asthma exacerbations, exhaled nitric oxide fraction, lung function, asthma control and quality of life questionnaire responses and sputum induction, and gave a blood sample at baseline, after 6 months and then every year...
November 2023: ERJ Open Research
https://read.qxmd.com/read/37987873/type-2-biomarkers-for-the-indication-and-response-to-biologics-in-crswnp
#29
REVIEW
Cui-Lian Guo, Fei-Fan Liu, De-Yun Wang, Zheng Liu
PURPOSE OF REVIEW: Three biologics targeting type 2 inflammation have been approved for the treatment of severe and uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP). Nevertheless, around 40-60% of patients do not respond well to these biological treatments. Selecting appropriate patients is crucial to improve treatment outcome of biologics. This review summarizes the literature data on type 2 biomarkers, with a specific focus on the indication to biologics for severe CRSwNP...
November 21, 2023: Current Allergy and Asthma Reports
https://read.qxmd.com/read/37984349/response-to-various-biologics-in-patients-with-both-asthma-and-chronic-obstructive-pulmonary-disease
#30
Marek Lommatzsch, Sebastian Niels Mohme, Paul Stoll, J Christian Virchow
INTRODUCTION: Patients can have features of both chronic obstructive pulmonary disease (COPD) and asthma. However, there is still no consensus how to precisely define this patient population. In addition, there are little data on the effectiveness of biologics in these patients. METHOD: Presence of COPD was defined by a smoking history of ≥10 pack years (PY), a postbronchodilator FEV1/FVC ratio &lt; lower limit of normal (LLN) and FEV1 &lt; 80% predicted, a carbon monoxide diffusion capacity (DLCO) &lt; LLN, and dyspnoea on exertion as a leading symptom...
2023: Respiration; International Review of Thoracic Diseases
https://read.qxmd.com/read/37972921/efficacy-and-safety-of-biologics-for-oral-corticosteroid-dependent-asthma-a-systematic-review-and-network-meta-analysis
#31
JOURNAL ARTICLE
Phichayut Phinyo, Thanachit Krikeerati, Irin Vichara-Anont, Torpong Thongngarm
BACKGROUND: A maintenance oral corticosteroid (OCS) in addition to high-dose inhaled corticosteroids plus long-acting β2 -agonists in patients with severe asthma leads to long-term adverse events. Oral corticosteroid-sparing agents are of high priority. OBJECTIVE: This network meta-analysis assessed biologics' comparative efficacy and safety in OCS-dependent patients with asthma. METHODS: We performed a systematic search through PubMed, Scopus, Embase, the Cochrane Center of Controlled Trials, and Google Scholar for randomized controlled trials that addressed the efficacy and safety of biologics compared with placebo in OCS-dependent patients with asthma from inception to July 2023...
February 2024: Journal of Allergy and Clinical Immunology in Practice
https://read.qxmd.com/read/37937490/benralizumab-in-severe-eosinophilic-asthma-a-real-world-single-center-observational-study-from-mexico
#32
JOURNAL ARTICLE
Miguel Reyes José Luis, López Estrada Erika Del Carmen, Arroyo Rojas Monserrat Arroyo, Salas Hernández Jorge, Castañeda Valdivia Mauricio, Escobar Preciado Monserrat, Cano Salas Maria Del Carmen
INTRODUCTION: Urbanization has increased the prevalence of asthma in lower- and middle-income countries. Severe eosinophilic asthma (SEA), a subtype of asthma, can be refractory to standard therapy. Biologics such as benralizumab target interleukin-5 and have demonstrated effectiveness in managing SEA. There exists no real-world evidence on the effectiveness of benralizumab in Mexico. Therefore, this study presents data on the role of benralizumab in managing SEA in Mexican patients. OBJECTIVE: The effectiveness of benralizumab on the quality of life (QoL), asthma control, lung function, symptoms of asthma, and benralizumab's safety profile were assessed...
2023: Allergologia et Immunopathologia
https://read.qxmd.com/read/37908397/real-world-characteristics-of-super-responders-to-mepolizumab-and-benralizumab-in-severe-eosinophilic-asthma-and-eosinophilic-granulomatosis-with-polyangiitis
#33
JOURNAL ARTICLE
Andrea Portacci, Raffaele Campisi, Enrico Buonamico, Santi Nolasco, Corrado Pelaia, Nunzio Crimi, Alida Benfante, Massimo Triggiani, Giuseppe Spadaro, Maria Filomena Caiaffa, Giulia Scioscia, Aikaterini Detoraki, Giuseppe Valenti, Francesco Papia, Alessandra Tomasello, Nicola Scichilone, Girolamo Pelaia, Claudia Crimi, Giovanna Elisiana Carpagnano
BACKGROUND: The current definition of severe eosinophilic asthma (SEA) super-responders to biologic treatment does not include patients with other eosinophil-based comorbidities. Although eosinophilic granulomatosis with polyangiitis (EGPA) is frequently associated with SEA, we lack data on a possible super-response to biologic treatments in patients suffering from these two diseases. We aim to assess super-responder features in real-life patients with SEA and EGPA treated with mepolizumab and benralizumab...
September 2023: ERJ Open Research
https://read.qxmd.com/read/37897876/real-world-super-response-to-biologics-in-severe-asthma-a-french-monocentric-retrospective-cohort-study
#34
JOURNAL ARTICLE
Solène Valéry, Stéfanie Habib-Maillard, Nicolas Roche
BACKGROUND: Biologics have dramatically improved outcomes in severe T2-high asthma. Although the identification of patients with the best response is key to understand the efficacy of these agents and select the best target populations, the definition and predictors of super-response are not fully established yet. METHODS: This study aimed to describe super-response and to identify predictors of super-response to biologics in a French severe eosinophilic asthma cohort followed in a severe asthma tertiary care center between January 2005 and December 2020...
October 8, 2023: Respiratory medicine and research
https://read.qxmd.com/read/37869947/biologics-in-allergic-rhinitis
#35
REVIEW
N Bayar Muluk, C Cingi
This paper aims to review biologics in allergic rhinitis (AR). Biologic agents of Omalizumab, Dupilumab, Mepolizumab, Reslizumab, and Benralizumab are reviewed in detail. The search is performed in "Pubmed," "Google," Google Scholar" and EBSCO Academic Search Ultimate (EKUAL) database of Kırıkkale University Library from 2021 to 2000, and randomized and/or placebo-controlled studies, review papers, meta-analysis, and reports are taken into consideration. The search was performed with the keywords of "allergic rhinitis," "biologics," "biologic agents," "Omalizumab," "Dupilumab," "Mepolizumab," "Reslizumab," "Benralizumab," "Anti IgE," "Anti-IL-4/IL-13", "Anti IL-5"...
October 2023: European Review for Medical and Pharmacological Sciences
https://read.qxmd.com/read/37796731/a-cost-comparison-of-benralizumab-mepolizumab-and-dupilumab-in-patients-with-severe-asthma-a-us-third-party-payer-perspective
#36
JOURNAL ARTICLE
Xiao Xu, Caroline Schaefer, Agota Szende, Eduardo Genofre, Rohit Katial, Yen Chung
BACKGROUND: Clinical trials and real-world evidence (RWE) studies of biologics have demonstrated reduced exacerbations, decreased use of oral corticosteroids (OCS), and improvements in daily symptoms and health-related quality of life in patients with severe eosinophilic asthma (SEA). OBJECTIVE: To compare direct health care costs associated with biologic use for the treatment of SEA from a US third-party payer perspective. METHODS: We developed a cost-minimization model to compare costs and cost offsets associated with 3 biologics-benralizumab, mepolizumab, and dupilumab-for 2- and 4-year periods...
October 5, 2023: Journal of Managed Care & Specialty Pharmacy
https://read.qxmd.com/read/37779519/medium-term-repeatability-for-airwave-oscillometry-in-patients-with-severe-asthma-taking-benralizumab
#37
JOURNAL ARTICLE
Rory Chan, Brian Lipworth
BACKGROUND: The effort-independent tidal breathing test used by oscillometry presents a viable alternative for following up patients whose condition is stable while they are receiving biologic therapy. OBJECTIVE: We aimed to determine intrasession and intersession repeatability values for airwave oscillometry (AOS) and spirometry in patients who were already taking benralizumab. METHODS: In all, 21 patients with severe eosinophilic asthma attended the Scottish Centre for Respiratory Research as part of a clinical trial (EudraCT identification number 2019-003763-22)...
August 2023: J Allergy Clin Immunol Glob
https://read.qxmd.com/read/37770889/achieving-clinical-outcomes-with-benralizumab-in-severe-eosinophilic-asthma-patients-in-a-real-world-setting-orbe-ii-study
#38
JOURNAL ARTICLE
Alicia Padilla-Galo, Isabel Moya Carmona, Pilar Ausín, Luis Carazo Fernández, Ismael García-Moguel, José Luis Velasco-Garrido, Rubén Andújar-Espinosa, Francisco Casas-Maldonado, Eva Martínez-Moragón, Carlos Martínez Rivera, Elisabet Vera Solsona, Fernando Sánchez-Toril López, Andrea Trisán Alonso, Marina Blanco Aparicio, Marcela Valverde-Monge, Borja Valencia Azcona, Marta Palop Cervera, Javier Nuevo, Jesús Sánchez Tena, Gustavo Resler, Elisa Luzón, Alberto Levy Naon
BACKGROUND: The ORBE II study aimed to describe the characteristics and clinical outcomes of adult patients with severe eosinophilic asthma (SEA) treated with benralizumab in a real-world setting in Spain. METHODS: ORBE II (NCT04648839) was an observational, retrospective cohort study in adult SEA patients who had been prescribed benralizumab. Demographic and clinical data of 204 SEA patients were collected 12 months prior to benralizumab initiation (baseline) and at follow-up...
September 28, 2023: Respiratory Research
https://read.qxmd.com/read/37749027/-biologics-in-severe-childhood-asthma
#39
REVIEW
F Amat
INTRODUCTION: Severe asthma in children remains relatively rare. It is no longer considered as a single disease but rather as a syndrome corresponding to different phenotypes and distinct pathophysiological pathways. Various biomarkers can contribute to phenotyping, essentially specific IgE test results, blood eosinophil counts, the exhaled fraction of NO (FeNO) assay, as well as deep lung biomarkers from induced sputum, bronchoalveolar lavage or bronchial biopsy. STATE OF KNOWLEDGE: In children, the biologics currently approved for severe asthma are omalizumab, mepolizumab and dupilumab from the age of 6, and tezepelumab from the age of 12...
October 2023: Revue des Maladies Respiratoires
https://read.qxmd.com/read/37737844/safety-and-efficacy-of-benralizumab-in-elderly-subjects-with-severe-asthma
#40
JOURNAL ARTICLE
Marcela Valverde-Monge, Remedios Cárdenas, Ismael García-Moguel, Ana Rosado, Mar Gandolfo-Cano, Teresa Robledo Echarren, María Del Mar Moro-Moro, María Del Mar Reaño Martos, Rafael Pineda-Pineda, Cristina Martin-Arriscado Arroba, Javier Domínguez-Ortega
INTRODUCTION: The prevalence of asthma in adults >65 years old is approximately 12-14%, and 10% have severe asthma. A higher mortality rate is observed in subjects with asthma >65 years old and especially >80 years old. OBJECTIVE: To analyze the effectiveness and safety of at least three doses of benralizumab in a subgroup of elderly subjects (>65 years old) with uncontrolled severe eosinophilic asthma in real-life conditions...
September 22, 2023: Journal of Asthma
keyword
keyword
165749
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.